• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Takeda Pharmaceutical Company Limited - Articles and news items

Takeda & TiGenix announce Perianal Fistulas trial treatment results in patients with Crohn's disease

Takeda & TiGenix announce Perianal Fistulas trial treatment results for Crohn’s disease

Industry news / 2 August 2016 / Takeda Pharmaceutical Company Limited / TiGenix NV

Takeda and TiGenix announce that the results of the Phase 3 ADMIRE-CD trial investigating Cx601 have been published. Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease…

Takeda & Seattle Genetics announce positive data from trial for cutaneous T-cell lymphoma 

Takeda and Seattle Genetics announce positive data from trial for cutaneous T-cell lymphoma 

Industry news / 1 August 2016 / Takeda Pharmaceutical Company Ltd and Seattle Genetics, Inc.

Takeda and Seattle Genetics announce that the ALCANZA trial evaluating ADCETRIS for cutaneous T-cell lymphoma demonstrated significant improvement…

adcetris

Five-year data from Phase II trial of Adcetris published

Industry news / 19 July 2016 / Victoria White, Digital Content Producer

The data comes from a Phase II trial of Adcetris (brentuximab vedotin) in patients with relapsed or refractory classical Hodgkin lymphoma…

ibd unmasked

IBD Unmasked – helping to shift perceptions of IBD

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Collaborating with Marvel Custom Solutions, Takeda’s IBD Unmasked initiative features an IBD Super Hero, Samarium, and a graphic novel series…

smc

SMC accepts five new medicines for use in NHS Scotland

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib…

adcetris

EC extends conditional marketing authorisation for Adcetris

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

The EC has extended the current conditional marketing authorisation of Adcetris as consodlidation treatment in post-transplant Hodgkin lymphoma…

cx601

Takeda enters into licensing agreement for ex-US rights to Cx601

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in Crohn’s disease…

gastroparesis

Takeda partners with Altos to develop compound for gastroparesis

Industry news / 4 July 2016 / Victoria White, Digital Content Producer

Takeda and Altos have entered into an agreement to further the develop Altos’s proprietary compound ATC-1906 for the treatment of gastroparesis…

norovirus

Takeda starts World’s first norovirus vaccine field trial

Industry news / 21 June 2016 / Victoria White, Digital Content Producer

Takeda has dosed the first subject in a Phase IIb field efficacy trial of its norovirus vaccine candidate, TAK-214…

orien

Takeda and M2Gen team up with ORIEN to speed drug development

Industry news / 17 June 2016 / Victoria White, Digital Content Producer

Takeda and M2Gen are to collaborate with ORIEN to speed the development of cancer therapeutics through health informatics…

myovant

Takeda and Roivant launch Myovant Sciences Ltd

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

Myovant Sciences is a biopharmaceutical company focused on delivering innovative women’s health and prostate cancer therapeutics…

Adcetris

Positive CHMP opinion for Adcetris in post-transplant Hodgkin lymphoma

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

The opinion is for Adcetris for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following ASCT…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +